Arecor Therapeutics PLC (AREC) AI Stock Analysis

• Market Cap: £27.00M
• Dividend Yield: N/A
• Average Volume (3M): 27.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: 3.31%
• EPS Growth: 21.91%
• Country: UK
• Employees: 50
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 37,756,600
• 10 Day Avg. Volume: 16,024
• 30 Day Avg. Volume: 27,661
• PEG Ratio: -0.22
• Price to Book (P/B): 4.59
• Price to Sales (P/S): 4.86
• P/FCF Ratio: -2.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: 70.00p ▼(-3.45% Downside)

Arecor Therapeutics PLC's overall stock score is primarily influenced by its financial performance and valuation challenges. The company is in a growth phase with increasing revenues but faces significant operational and cash flow challenges typical of early-stage biotech firms. Technical analysis indicates short-term bearish momentum, although there is some longer-term support. The negative P/E ratio and lack of dividend yield reflect ongoing profitability struggles and reinvestment in growth.

Arecor Therapeutics PLC Business Overview & Revenue Model

Company Description

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

How the Company Makes Money

Arecor Therapeutics PLC generates revenue through multiple streams. The company earns money by developing its proprietary drug formulations and licensing them to pharmaceutical companies, which pays Arecor for the rights to use its advanced formulation technology. Additionally, Arecor engages in partnerships and collaborations with other pharmaceutical and biotechnology firms, receiving milestone payments and royalties based on the success and commercialization of the partnered products. These partnerships are crucial as they provide funding for research and development, which is a significant part of its business model. Furthermore, the company may also generate income from grants and government funding aimed at supporting innovative healthcare solutions.

Arecor Therapeutics PLC Financial Statement Overview

Summary

Arecor Therapeutics PLC is in a growth phase with increasing revenue but faces challenges with negative net income and cash flow issues typical of early-stage biotech firms. The balance sheet shows a strong equity position but a concerning debt-to-equity ratio.

Income Statement

Arecor Therapeutics PLC has shown significant revenue growth over the years, with a notable increase from 2022 to 2023. However, the company consistently reports negative net income and EBIT, which indicates operational challenges in maintaining profitability. Gross profit margin has significantly declined in 2023 from previous levels due to increasing costs. The negative EBIT and EBITDA margins highlight the ongoing struggle to generate positive operating income, characteristic of early-stage biotech firms focusing on R&D.

Balance Sheet

The balance sheet reveals a strong equity position, with a significant portion of the total assets funded by stockholders' equity, reflected in the equity ratio. However, the company has a concerning debt-to-equity ratio and a shrinking asset base, which could pose risks if cash reserves continue to deplete without achieving profitability. Despite this, low debt levels suggest manageable leverage.

Cash Flow

Cash flow statements show negative operating and free cash flows, emphasizing heavy cash burn typical for biotech companies at this stage. While the company raised capital through financing activities, the continuous negative free cash flow growth rate flags sustainability concerns if the trend persists. The operating cash flow to net income ratio highlights a challenging conversion of revenue into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.06M	5.05M	4.57M	2.40M	1.16M	1.70M
Gross Profit	-344.00K	1.54M	4.57M	2.40M	1.16M	1.70M
EBITDA	-8.02M	-10.15M	-8.39M	-10.06M	-6.27M	-3.26M
Net Income	-8.10M	-10.24M	-8.55M	-9.26M	-6.17M	-2.75M
Balance Sheet
Total Assets	5.25M	8.72M	15.38M	21.77M	20.92M	4.28M
Cash, Cash Equivalents and Short-Term Investments	1.89M	3.26M	6.75M	12.81M	18.32M	2.90M
Total Debt	173.00K	232.00K	338.00K	288.00K	231.00K	2.00M
Total Liabilities	2.39M	3.37M	5.85M	4.31M	2.37M	3.51M
Stockholders Equity	2.86M	5.35M	9.53M	17.45M	18.55M	773.79K
Cash Flow
Free Cash Flow	-6.20M	-9.18M	-5.99M	-11.13M	-5.52M	-1.91M
Operating Cash Flow	-6.09M	-9.15M	-5.84M	-10.78M	-5.45M	-1.86M
Investing Cash Flow	1.00K	1.72M	6.52M	-7.99M	-68.00K	-49.32K
Financing Cash Flow	5.64M	5.65M	-180.00K	5.16M	20.93M	1.77M

Arecor Therapeutics PLC Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 72.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AREC, the sentiment is Neutral. The current price of 72.5 is below the 20-day moving average (MA) of 75.08, below the 50-day MA of 73.53, and above the 200-day MA of 54.64, indicating a neutral trend. The MACD of -1.21 indicates Positive momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of 44.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:AREC.

Arecor Therapeutics PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRX	―	£5.16M	-4.90	-5.41%	―	-20.31%	-19.35%
SAR	―	£18.64M	-5.63	-101.07%	―	―	45.70%
AREC	―	£27.00M	―	-204.29%	―	3.31%	21.91%

Arecor Therapeutics PLC Corporate Events

Arecor Therapeutics Strengthens Board with Key Appointments

Arecor Therapeutics plc has announced significant changes to its Board, appointing Simon Ormiston as a Non-Executive Director and Chair of the Audit & Risk Committee, and elevating David Ellam, the Chief Financial Officer, to an Executive Director role. These changes are part of a strategic plan to strengthen the company’s governance and support its growth ambitions in the life sciences sector, particularly as it pursues strategic collaborations and monetization agreements.

The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.

Arecor Partners with Sequel for Advanced Insulin Delivery, Secures $11M Funding

Arecor Therapeutics has entered a co-development agreement with Sequel Med Tech to advance its ultra-concentrated insulin, AT278, in combination with Sequel’s advanced insulin delivery system. This partnership aims to address unmet needs in diabetes management and represents a strategic milestone for Arecor, enhancing its market positioning and extending its cash runway to 2027. Additionally, Arecor has secured up to $11 million in non-dilutive funding through a royalty financing agreement with Ligand Pharmaceuticals, which will support the development of AT278 and strengthen its financial stability.

The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.

Arecor Therapeutics Advances Diabetes and Obesity Drug Development with Strategic Partnerships

Arecor Therapeutics plc reported its interim results for the first half of 2025, highlighting significant progress in its diabetes and obesity drug development portfolios. The company received positive FDA feedback for its AT278 insulin product and signed a co-development agreement with Sequel Med Tech for Phase 2 activities, extending its cash runway to 2027. The company also made strides in its oral peptide delivery platform, aiming to improve patient accessibility and outcomes in the growing peptide therapeutics market. Financially, Arecor maintained steady revenue, reduced losses, and secured a royalty financing agreement with Ligand Pharmaceuticals, bolstering its financial position.

The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.

Arecor Therapeutics to Announce Interim Results

Arecor Therapeutics plc announced it will release its interim results for the first half of 2025 on 25 September. The announcement will be followed by a webcast hosted by the company’s CEO and CFO for analysts and institutional investors, highlighting the company’s ongoing commitment to transparency and engagement with stakeholders. This release is significant as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.

Arecor Therapeutics Secures FDA Approval for Innovative Insulin Study Design

Arecor Therapeutics plc has received positive feedback from the FDA on the design of its Phase 2 clinical study for AT278, an ultra-concentrated and ultra-rapid acting insulin, in combination with an Automated Insulin Delivery (AID) system. This feedback marks a significant milestone for Arecor, enabling faster development by using Time-in-Range (TIR) as a primary efficacy endpoint, which provides real-time insights into glycaemic variability. The study, set to commence in 2026, aims to demonstrate the economic value and patient benefits of AT278 and could potentially disrupt the insulin treatment market by addressing unmet needs in diabetes care.

The most recent analyst rating on (GB:AREC) stock is a Hold with a £68.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.

Arecor Therapeutics Appoints New Auditor PKF Littlejohn LLP

Arecor Therapeutics plc has announced a change in its auditor, appointing PKF Littlejohn LLP to succeed Grant Thornton UK LLP following a formal tender process. This change is part of the company’s ongoing efforts to ensure robust financial oversight, with PKF set to audit the financial statements for the year ending December 2025. The appointment will be subject to shareholder approval at the 2026 Annual General Meeting, reflecting Arecor’s commitment to transparency and effective governance.